Juvenile idiopathic arthritis natural history, complications and prognosis
|
Juvenile idiopathic arthritis Microchapters |
|
Differentiating Juvenile idiopathic arthritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Juvenile idiopathic arthritis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Juvenile idiopathic arthritis natural history, complications and prognosis |
|
FDA on Juvenile idiopathic arthritis natural history, complications and prognosis |
|
CDC on Juvenile idiopathic arthritis natural history, complications and prognosis |
|
Juvenile idiopathic arthritis natural history, complications and prognosis in the news |
|
Blogs on Juvenile idiopathic arthritis natural history, complications and prognosis |
|
Directions to Hospitals Treating Juvenile idiopathic arthritis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dheeraj Makkar, M.D.[2] Nehal Eid, M.D.[3]
Overview
Juvenile idiopathic arthritis may lead to significant articular and extra-articular complications, including joint damage, growth disturbances, ocular disease, and systemic inflammatory sequelae. The risk and severity of complications vary by disease subtype and duration of uncontrolled inflammation. Early diagnosis and timely initiation of effective therapy are critical to minimizing long-term morbidity and preserving function. Before the 2000s, 25 to 40% of JIA cases had moderate-to-severe disease, with lifelong complications.[1][2] Since the development of the new anti-inflammatory, biologic disease-modifying antirheumatic drugs (DMARDs) in 1999, there has been a noticeable decrease in joint destruction, joint deformities, and disease-related disability previously seen in patients with JIA.
Natural History
The natural history of juvenile idiopathic arthritis (JIA) is heterogeneous and varies according to disease subtype, age at onset, and response to therapy. Disease course may be monophasic, relapsing–remitting, or persist into adulthood. Treatment-free remission is uncommon, with many patients needing treatment in adulthood. Up to 70% achieve meaningful disease control with modern therapies. Disease flares are common after therapy stoppage ranging from 30% up to 100%. 50% of patients don't fully regain control after disease flare.
- Some patients experience a self-limited course with remission within months to years
- Others develop chronic, progressive arthritis with joint damage and functional impairment
- Oligoarticular JIA may remain limited or progress to extended disease. 50% of patients have persistent oligoarticular course, the other 50% have extended disease. High ESR and wrist/ankle affection predict extensive course.
- Symptomatic axial involvement (sacroillitis, inflammatory spine disease, or both) develops in 40 to 60% of patiets withh enthesitis related arthritis. Asymptomatic sacroillitis is present in 30% of patients at time of disease onset.
- Polyarticular JIA is more likely to follow a chronic course, particularly in RF-positive disease
- Systemic JIA may evolve from predominant systemic inflammation to chronic destructive arthritis
Extra-articular complications, including uveitis, growth disturbances, lung disease and macrophage activation syndrome, may influence long-term outcomes. Advances in early diagnosis and biologic therapy have significantly improved disease control and functional prognosis. [3]
Complications
Juvenile idiopathic arthritis (JIA) may be associated with a range of articular and extra-articular complications that vary by disease subtype, severity, and duration of inflammation.
Lung Disease Associated with Systemic JIA:
A serious complication in patients with systemic JIA is lung disease, which can cause hypoxic respiratory failure and even death.[4][5] The prevalence of lung disease among patients with systemic JIA is increasing and appears to be temporally associ ated with the increased use of interleukin-1 and interleukin-6 inhibitors. Children with systemic JIA and lung disease are generally younger at diagnosis and have more severe systemic disease (including macrophage activation syndrome).
Musculoskeletal Complications
- Chronic synovitis leading to joint damage and deformity
- Reduced range of motion and functional impairment
- Limb-length discrepancy due to asymmetric growth at epiphyseal growth plates as a result of inflammatory hyperemia.[6]
- Temporomandibular joint involvement causing facial asymmetry and micrognathia.[7] Usage of contrast enhanced MRI helps in early detection of temporomandibular joint arthritis and timely treatment may prevent severe micrognathia, facial deformities, heterotopic calcification, and jaw dysfunction.[8]
- Growth retardation related to chronic inflammation or glucocorticoid exposure before DMARD development
Ocular Complications
Chronic anterior uveitis:
- Prevalence: It presents within 10 to 30% of patients, according to JIA classification, with highest prevalence among girls under 6 years with positive ANA.[9] It is particularly common in ANA-positive oligoarticular and RF-negative polyarticular JIA or psoriatic arthritis.[10]It is less common in older ages and rare in systemic JIA, RF-positive polyarticular JIA, or enthesitis-related arthritis. 90% of cases occur within 4 years of disease onset.
- Complications: Increased risk of cataracts, glaucoma, band keratopathy, and vision loss if untreated
- Screening: Ophthalmologic proactive screening is recommended every 3 to 6 months for several years after diagnosis due to asymptomatic initial disease course.[11][12][13]
- Treatment: Topical glucocorticoid eye drops can be used initially, but more than 40% eventually require systemic therapy, usually with methotrexate, a TNF inhibitor, or both.[14]
Acute anterior uveitis:
It affects 11 to 13% of JIA patients. It is usually seen in enthesitis-related arthritis. It presents as rapid onset ophthalmoplegia, conjunctival erythema and photophobia. It responds well to topical glucocorticoids but systemic DMARDS should be considered in case of two or three annual episodes of acute anterior uveitis.
Systemic and Inflammatory Complications
- Macrophage activation syndrome, a life-threatening hyperinflammatory state most commonly associated with systemic JIA, it is prevalent in at least 10% of patients with systemic JIA.[15] It can occur at any point in the disease progression. Affected patients present with fever, coagulopathy, cytopenias, hyperferritinemia, liver injury, and central nervous system dysfunction.[16] Patients often have marked elevation of IL-18 inducing Interferon-gamma production.[17] [18]Interferon gamma inhibitors are effective in treatment.[19] Other therapeutic modalities include high dose glucocorticoids and high dose IL-1 inhibitors.[20]
- Serositis, including pericarditis and pleuritis
- Interstitial lung disease and pulmonary hypertension, particularly in systemic JIA with increasing prevalence that appears to be temporally associated with IL-1 and IL-6 inhibitors. Several pathogenesis hypotheses involving treatment with IL-1 and IL-6 inhibitors have been proposed, including cytokine-related lymphocyte plasticity and an unusual pulmonary complication of drug induced hypersensitivity syndrome.[21][22] More studies are needed to determine disease pathogenesis, as well as effective approaches to identification, screening, and management.[23][24] Children with systemic JIA and lung disease are often diagnosed earlier and have more severe systemic disease.
Psychosocial and Long-Term Complications
- Chronic pain and fatigue
- Impaired quality of life and psychosocial stress
- Persistence of active disease into adulthood requiring long-term rheumatologic care
Early recognition and appropriate treatment are essential to reduce the risk of long-term complications and improve functional outcomes.
Possible complications
- Wearing away or destruction of joints (can occur in patients with more severe JRA)
- Slow rate of growth
- Uneven growth of an arm or leg
- Loss of vision or decreased vision from chronic uveitis (this problem may be severe, even when the arthritis is not very severe)
- Anemia
- Swelling around the heart (pericarditis)
- Chronic pain, poor school attendance
Prognosis
The prognosis of juvenile idiopathic arthritis (JIA) is variable and depends on disease subtype, age at onset, severity of inflammation, and response to treatment. Many patients achieve clinical remission with modern therapy, while others experience persistent or relapsing disease.
- Oligoarticular JIA generally has a favorable prognosis, particularly when disease remains limited
- Polyarticular JIA, especially RF-positive disease, is more likely to follow a chronic and erosive course
- Systemic JIA may be monophasic, relapsing, or evolve into chronic arthritis
- Early diagnosis and use of biologic therapies are associated with improved functional outcomes
- Some patients continue to have active disease or disability into adulthood
Overall, advances in early intervention and targeted biologic treatments have significantly improved long-term outcomes and quality of life for many patients with JIA.
JRA is seldom life threatening. Children who have many joints involved, or who have a positive rheumatoid factor are more likely to have chronic pain and poor school attendance, and to be disabled.
Long periods with no symptoms are more common in those who have only a small number of joints involved. Many patients with JRA eventually go into remission with very little loss of function and deformity.
References
- ↑ Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41: 1428-35.
- ↑ Oen K, Malleson PN, Cabral DA, Rosenberg AM, Petty RE, Cheang M. Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol 2002; 29: 1989-99.
- ↑ Sandborg CI, Schulert GS, Kimura Y. Juvenile Idiopathic Arthritis. N Engl J Med. 2025;392:XXX–XXX. doi:10.1056/NEJMra2402073.
- ↑ Schulert GS, Yasin S, Carey B, et al. Systemic juvenile idiopathic arthritis associated lung disease: characterization and risk factors. Arthritis Rheumatol 2019; 71:1943-54.
- ↑ Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019; 78: 1722-31.
- ↑ Vostrejs M, Hollister JR. Muscle atrophy and leg length discrepancies in pauciarticular juvenile rheumatoid arthritis. Am J Dis Child 1988; 142: 343-5.
- ↑ Stoll ML, Sharpe T, Beukelman T, Good J, Young D, Cron RQ. Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. J Rheumatol 2012; 39: 1880-7.
- ↑ Stoustrup P, Resnick CM, Abramowicz S, et al. Management of orofacial mani festations of juvenile idiopathic arthritis: interdisciplinary consensus-based recom mendations. Arthritis Rheumatol 2023; 75: 4-14
- ↑ Wennink RAW, de Boer JH, Hiddingh S, et al. Next-generation HLA sequence analysis uncovers shared risk alleles between clinically distinct forms of childhood uveitis. Invest Ophthalmol Vis Sci 2021; 62:19.
- ↑ Petty RE, Laxer RM, Lindsley CB, Wedderburn LR, Mellins ED, Fuhlbrigge RC. Textbook of pediatric rheumatology. 8th ed. Philadelphia: Elsevier, 2021.
- ↑ Angeles-Han ST, Ringold S, Beukel man T, et al. 2019 American College of Rheumatology/Arthritis Foundation guide line for the screening, monitoring, and treatment of juvenile idiopathic arthritis associated uveitis. Arthritis Care Res (Hoboken) 2019; 71: 703-16.
- ↑ Foeldvari I, Maccora I, Petrushkin H, et al. New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken) 2023; 75: 975-82.
- ↑ Sen ES, Ramanan AV. Juvenile idio pathic arthritis-associated uveitis. Clin Im munol 2020; 211: 108322.
- ↑ Heiligenhaus A, Minden K, Tappeiner C, et al. Update of the evidence based, in terdisciplinary guideline for anti-inflam matory treatment of uveitis associated with juvenile idiopathic arthritis. Semin Arthritis Rheum 2019; 49: 43-55.
- ↑ Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014; 66: 3160-9.
- ↑ Ravelli A, Minoia F, Davì S, et al. 2016 classification criteria for macrophage ac tivation syndrome complicating system ic juvenile idiopathic arthritis: a Europe an League Against Rheumatism/American College of Rheumatology/Paediatric Rheu matology International Trials Organisa tion collaborative initiative. Ann Rheum Dis 2016; 75: 481-9.
- ↑ Yasin S, Solomon K, Canna SW, et al. IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage acti vation syndrome. Rheumatology (Oxford) 2020; 59: 442-5.
- ↑ Landy E, Carol H, Ring A, Canna S. Biological and clinical roles of IL-18 in inflammatory diseases. Nat Rev Rheuma tol 2024; 20: 33-47.
- ↑ De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis 2023; 82: 857-65.
- ↑ De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis 2023; 82: 857-65.
- ↑ Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis 2022; 81: 406-15.
- ↑ Binstadt BA, Nigrovic PA. The conun drum of lung disease and drug hypersen sitivity-like reactions in systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2022; 74: 1122-31.
- ↑ Wobma H, Arvila SR, Taylor ML, et al. Incidence and risk factors for eosinophilia and lung disease in biologic-exposed children with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2023; 75: 2063-72.
- ↑ Saper VE, Tian L, Verstegen RHJ, et al. Interleukin (IL)-1/IL-6-inhibitor-associat ed drug reaction with eosinophilia and systemic symptoms (DReSS) in systemic inflammatory illnesses. J Allergy Clin Im munol Pract 2024; 12(11): 2996-3013.e7.
- ↑ Sandborg CI, Schulert GS, Kimura Y. Juvenile Idiopathic Arthritis. N Engl J Med. 2025;392:XXX–XXX. doi:10.1056/NEJMra2402073.
- ↑ Sandborg CI, Schulert GS, Kimura Y. Juvenile Idiopathic Arthritis. N Engl J Med. 2025;392:XXX–XXX. doi:10.1056/NEJMra2402073.